ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.

Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). Current ET treatments aim to normalize hematological parameters and reduce the thrombotic risk, but they do not modify the natural history of the disease and hence, have no impact on disease progression. Ropeginterferon alfa-2b (trade name BESREMi®), a novel, monopegylated interferon alfa-2b with an extended administration interval, has demonstrated a robust and sustained efficacy in polycythemia vera (PV) patients. Given the similarities in disease pathophysiology and treatment goals, ropeginterferon alfa-2b holds promise as a treatment option for ET. The ROP-ET trial is a prospective, multicenter, single-arm phase III study that includes patients with ET who are intolerant or resistant to, and/or are ineligible for current therapies, such as hydroxyurea (HU), anagrelide (ANA), busulfan (BUS) and pipobroman, leaving these patients with limited treatment options. The primary endpoint is a composite response of hematologic parameters and disease-related symptoms, according to modified European LeukemiaNet (ELN) criteria. Secondary endpoints include improvements in symptoms and quality of life, molecular response and the safety profile of ropeginterferon alfa-2b. Over a 3-year period the trial assesses longer term outcomes, particularly the effects on allele burden and clinical outcomes, such as disease-related symptoms, vascular events and disease progression. No prospective clinical trial data exist for ropeginterferon alfa-2b in the planned ET study population and this study will provide new findings that may contribute to advancing the treatment landscape for ET patients with limited alternatives. TRIAL REGISTRATION: EU Clinical Trials Register; EudraCT, 2023-505160-12-00; Registered on October 30, 2023.

Intra-articular osteoma in the stifle joint of a cat.

Case summary: A 13-year-old male castrated cat was referred to our clinic for a 2-month history of right hindlimb lameness. Radiographs and CT showed a solid bony mass within the stifle joint. The mass was resected by arthrotomy and osteotomy of the tibial tuberosity. Histopathological examination revealed the diagnosis of osteoma. Recovery from surgery was uneventful. At the 8-week follow-up examination, the cat was free of clinical signs. Relevance and novel information: Feline osteomas are rare; only few cases have been reported. To the best of our knowledge, this is the first report of an intra-articular osteoma in the stifle joint of a cat and description of its surgical resection.

Radiographically confirmed outcomes after fracture repair with a PLS polyaxial locking system in 40 dogs and cats.

OBJECTIVE: To report radiographic findings and complications after fracture repair with a new polyaxial locking plate system (PLS polyaxial locking system; Aesculap/B Braun, Tuttlingen, Germany) in dogs and cats. STUDY DESIGN: Retrospective case review from four veterinary practices. SAMPLE POPULATION: Twenty-six dogs and 14 cats (40 long bone fractures). METHODS: Medical and radiographic records of dogs and cats with long bone fractures treated with the PLS were reviewed. Cases were included when operative records were complete and included documentation of radiographic union or complications. Phone interviews of owners were performed for long-term follow-up. Ancillary methods of fracture fixation and associated complications were recorded. RESULTS: Only two complications were recorded, one of which required a revision surgery. Radiographic follow-up was performed for all fractures. Radiographic union without complications was achieved in 38 of 40 (95%) fractures. Radiographic union was documented before 60 days in 19 of 40 (47.5%) fractures, between 61 and 90 days in 15 of 40 (37.5%) fractures, and after 90 days in six of 40 (15%) fractures. A functional union was observed at a mean time ± SD of 70.8 ± 38.9 days (range, 32-182). One or more ancillary fixation methods were used in 27 of 40 (67.5%) fractures. CONCLUSION: The PLS polyaxial locking system was often used with adjunct fixation in this series, and radiographically confirmed healing without complications was documented in most cases. CLINICAL SIGNIFICANCE: Use of the PLS can result in high success rates for fracture repair in dogs and cats, but ancillary fixation should be strongly considered.

Early Clinical Experience with a Newly Designed Interlocking Nail System-Targon(®) Vet.

OBJECTIVE: To describe early clinical experience with a newly designed interlocking nail system (Targon(®) Vet) in diaphyseal fractures in cats and small dogs. STUDY DESIGN: Retrospective case series. ANIMALS: Client-owned cats (n=49) and dogs (n=8). METHODS: Fifty-seven consecutive cases (49 cats, 8 dogs) with 60 long bone fractures were included in the study. Follow-up radiographs were scheduled at 4 and 8 weeks and again 6 months postoperatively. The end point for each case was determined radiographically by a healed fracture. Complications were defined as minor or major. Clinical outcome was subjectively assessed by a full orthopedic examination and follow-up radiographs. Descriptive data are reported. RESULTS: Median age of cats was 18 months (range, 3-220 months) and of dogs was 28 months (range, 7-115 months). Median body weight was 3.7 kg (range, 1.67-8.41 kg) for cats and 8.15 kg (range, 2.68-13.6 kg) for dogs. Median radiographic follow-up was 16 weeks. All fractures with follow-up radiographs available (n=46) were healed with no infections reported. A total of 12 postoperative complications occurred: 3 minor (slippage of the locking screws) and 9 major (5 femoral-irritation of the sciatic nerve, stress protection, fracture because of a missed fissure, femoral neck fracture, intra-operative revision with a rod and plate; 4 tibial-3 with protrusion of the distal locking screw through the skin and 1 with in-growth of the intramedullary nail). CONCLUSION: Implantation of the Targon(®) Vet System was feasible in all cases. It provides an alternative system for diaphyseal fracture repair in cats and small dogs.